ArticleHaematologica2025

First-in-human pharmacokinetic, safety, and preliminary efficacy studies of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A.

Feng Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.